Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin for HPV-Related Malignancies
NCT02308241Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2014
- Primary completion
- Mar 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of ribavirin in HPV-related carcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Radiographic Responses, Determined by RECIST 1.1 Criteria at 1 year. Started Dec 2014; status: completed.
02
Drugs
ribavirin
03
Conditions
HPV-related carcinoma
Beyond the preview
Go deeper on NCT02308241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02308241.